---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-006344"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-08-13T20:15:36+00:00"
generated_at: "2026-08-13T20:17:32.018854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports Q1 FY2027 results; cash $4.9M, raises $4M post-quarter

## Summary
- Cash and cash equivalents ~$4.9M as of June 30, 2026; raised ~$4.0M gross in public offering after quarter-end.
- Operating expenses decreased 11.9% to ~$1.6M vs $1.8M in prior-year quarter.
- First participant dosed in third/final cohort of Phase 1 oncology study in Australia; early biomarker signals support Hemopurifier.
- Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.
- Company believes cash resources sufficient to fund operations for at least next 12 months.

## SEC filing metadata
- accession: 0001683168-26-006344
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-08-13T20:15:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/0001683168-26-006344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-006344
- JSON: https://secwatch.observer/filing/0001683168-26-006344.json
- Plain text: https://secwatch.observer/filing/0001683168-26-006344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.